Evidence map›Paper›PMID 30482263›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2018

Acute flaccid paralysis (AFP) surveillance: challenges and opportunities from 18 years' experience, Spain, 1998 to 2015.

Josefa Masa-Calles, Nuria Torner, Noemí López-Perea, María de Viarce Torres de Mier, Beatriz Fernández-Martínez, María Cabrerizo, Virtudes Gallardo-García, Carmen Malo, Mario Margolles, Margarita Portell and 17 more

Abstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. An imported case of vaccine-derived poliovirus type 2, Spain in the context of the ongoing polio Public Health Emergency of International Concern, September 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Polio eradication: next steps and future challenges.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Josefa Masa-CallesNational Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
Nuria TornerSpanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
Noemí López-PereaNational Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
María de Viarce Torres de MierNational Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
Beatriz Fernández-MartínezNational Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
María CabrerizoNational Polio Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Virtudes Gallardo-GarcíaServicio de Vigilancia y Salud Laboral, Consejería de Salud, Andalucía, Spain.
Carmen MaloServicio de Vigilancia en Salud Pública, D.G. de Salud Pública, Departamento de Sanidad, Aragón, Spain.
Mario MargollesServicio de Vigilancia Epidemiológica, Consejería de Sanidad, Instituto de Investigación Sanitaria del Principado de Asturias, Spain.
Margarita PortellServicio de Vigilancia Epidemiológica, Conselleria de Salut, Família i Bienestar Social Baleares, Spain.
Natividad AbadíaServicio de Epidemiologia y Prevención, Dirección General Salud Pública, Servicio Canario de Salud, Canarias, Spain.
Aniceto BlascoSección de Vigilancia Epidemiológica, D.G. de Salud Pública, Cantabria, Spain.
Sara García-HernándezServicio de Epidemiología, D.G. de Salud Pública, Consejería de Sanidad, Castilla-La Mancha, Spain.
Henar MarcosServicio de Vigilancia Epidemiológica y Enfermedades Transmisibles, D.G. de Salud Pública, Consejería de Sanidad, Castilla y León, Spain.
Núria RabellaMicrobiology Department, Hospital de la Santa Creu i Sant Pau, Microbiology & Genetics Department, Universitat Autònoma de Barcelona, Barcelona, Spain.
Celia MarínServei de Vigilància i Control Epidemiològic, Conselleria de Sanitat Universal i Salut Pública, Comunitat Valenciana, Spain.
Amelia FuentesSubdirección de Epidemiología. D.G. de Salud Pública, Servicio Extremeño de Salud, Consejería de Salud y Políticas Sociales, Extremadura, Spain.
Isabel LosadaServizo de Epidemioloxía, Dirección Xeral de Saúde Pública, Consellería de Sanidade, Xunta de Galicia, Spain.
Juan García GutiérrezServicio de Epidemiología, Subdirección General de Epidemiología, Dirección General de Salud Pública, Comunidad Autónoma de Madrid, Spain.
Alba NietoServicio de Epidemiología, Subdirección General de Epidemiología, Dirección General de Salud Pública, Comunidad Autónoma de Madrid, Spain.
Visitación García OrtúzarServicio de Epidemiología, D. G. de Salud Pública y Adicciones, Consejería de Salud, Región de Murcia, Spain.
Manuel García CenozSpanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
José María ArteagoitiaServicio de vigilancia epidemiológica y vacunas, Dirección de Salud Pública y Adicciones, Departamento de Salud, País Vasco, Spain.
Ángela Blanco MartínezSección de Vigilancia Epidemiológica y Control de Enfermedades Transmisibles, D.G de Salud Pública y Consumo, Consejería de Salud, La Rioja, Spain.
Ana RivasServicio de Epidemiología, Consejería de Sanidad y Consumo, Ceuta, Spain.
Daniel CastrillejoServicio de Epidemiología, D.G. de Sanidad y Consumo, Consejería de Presidencia y Salud Pública, Melilla, Spain.
Spanish AFP Surveillance Working GroupThe other members of the Spanish AFP Surveillance Working Group are listed at the end of this article.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute flaccid paralysis (AFP) surveillance is key for global polio eradication. It allows detecting poliovirus (PV) reintroductions from endemic countries. This study describes AFP surveillance in Spain from 1998 to 2015. During this time, 678 AFP cases were reported to the Spanish National Surveillance Network. The mean notification rate was 0.58 AFP cases/100,000 population under 15 years old (range: 0.45/100,000-0.78/100,000). Two periods (P) are described: P1 (1998-2006) with the AFP notification rate ranging from 0.66/100,000 to 0.78/100,000, peaking in 2001 (0.84/100,000); and P2 (2007-2015) when the AFP rate ranged from 0.43/100,000 to 0.57/100,000, with the lowest rate in 2009 (0.31/100,000). No poliomyelitis cases were caused by wild PV infections, although two Sabin-like PVs and one imported vaccine-derived PV-2 were detected. Overall, 23 (3.4%) cases met the hot case definition. Most cases were clinically diagnosed with Guillain-Barré syndrome (76.9%; 504/655). The adequate stool collection rate ranged from 33.3% (7/21) to 72.5% (29/40). The annual proportion of AFP cases with non-polio enterovirus findings varied widely across the study period. AFP surveillance with laboratory testing for non-polio enteroviruses must be maintained and enhanced both to monitor polio eradication and to establish sensitive surveillance for prompt detection of other enteroviruses causing serious symptoms.

Indexed as

AdolescentChildChild, PreschoolDisease EradicationDisease NotificationDisease OutbreaksFemaleHumansInfantMaleParalysisPoliomyelitisPoliovirusPoliovirus Vaccine, OralPoliovirus VaccinesPopulation SurveillancePoliovirus Vaccine, OralPoliovirus Vaccinesacute flaccid paralysis surveillanceenteroviruspoliomyelitis eradicationSpainsurveillancevaccine preventable disease

Identifiers

PMID30482263
PMCPMC6341937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.